Mphasis

Expect 2021 tech spend growth to be in mid-single digits – Mphasis

Update on the Indian Equity Market:
On Tuesday, Nifty 50 ended at an all-time high of 13,933 (+0.4%), as gains in the banking, IT, and Technology sectors propelled the index higher. Among the stocks, INDUSINDBK (+5.7%), TECHM (+2.2%), and AXISBANK (+2.1%) led the gainers while HINDALCO (-2.1%), NESTLEIND (-1.8%), and COALINDIA (-1.7%) led the laggards. PRIVATE BANK (+1.6%), BANK (+1.4%), and FINANCIAL SERVICES (+1.0%) led the sector gainers. MEDIA (-1.5%), METAL (-1.1%), and REALTY (-0.3%) led the sectoral losers.

Excerpts of an interview of Mr. Nitin Rakesh, CEO & Executive Director, Mphasis with CNBC TV18 on 29th December 2020:
• Mphasis has witnessed a good expansion of deal pipeline in the last 3-4 quarters but the type of deals is different. The conversation has been about transformation deals, and acceleration of the work done for clients, such as the adoption of application transformation, and moving work to the cloud.
• Their guidance for a pretty strong year in the direct business remains on track. There were 87% (in terms of Total Contract Value (TCV)) more deals done in 1HFY21 compared to 1HFY20. This is expected to translate nicely to the overall revenue momentum.
• The pipeline is pretty strong in terms of the size of deals, the number of deals, and the nature of deals are very encouraging.
• They are expanding their business in Europe, which was resilient to lockdowns in certain areas. Mr. Rakesh feels the impact of these lockdowns needs to be seen on the sales pipeline. In the short to medium term, he believes they are good to sustain through the lockdowns.
• The growth in the business has been broad-based. Hi-tech, banking, logistics – these segments have done well.
• He believes the recovery post the Covid-19 crisis will be different compared to the recoveries from the Y2K crisis and the global financial crisis. This is primarily due to shifting in consumption patterns from a technological standpoint, which will change the importance of technology in every business. Second, the type of competency and capability required is going to be different.
• The market opportunity will exist over the next 3 years. The total tech spend will go up probably higher than it has been in the last 3-5 years. The tech spends are expected to grow in mid-single digits in CY21.
• He believes Mphasis will see above-market growth.
• Mphasis has a pretty robust investment plan. There has been investment in two new tribes in the last six months- Experience and Everything as a platform. They are also investing ahead of the curve in areas such as Quantum Computing.
• The entire value chain that involves all things cloud, AI and machine learning will the areas where Mphasis will keep investing.

Consensus Estimate: (Source: market screener website)
• The closing price of Mphasis was ₹ 1,555/- as of 29-December-2020. It traded at 24x/ 20x/ 18x the consensus earnings estimate of ₹ 66/ 77 /87 per share for FY21E/FY22E/FY23E respectively.
• The consensus target price of ₹ 1,569 implies a PE multiple of 18x on FY23E EPS of ₹ 87/-.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Prioritizing growth over margin expansion– Mphasis

Update on the Indian Equity Market:

On Monday, Nifty closed 1.4% lower at 11,768. Within NIFTY50, HDFCLIFE (+3.2%), NSETLEIND (+2.6%), and KOTAKBANK (+2.0%) were the only gainers, while HEROMOTOCO (-6.7%), BAJAJ-AUTO (-6.0%), and HINDALCO (-5.3%) were the top losing stocks. All the sectoral indices closed with losses led by METAL (-3.5%), AUTO (-3.2%), and MEDIA (-2.7%).

Prioritizing growth over margin expansion– Mphasis

Excerpts of an interview with Mr. Nitin Rakesh, MD & CEO, Mphasis, aired on CNBC-TV19 on 23rdOctober 2020:
● Mphasis delivered a strong growth in Direct Core segment in 2QFY21. The growth has been broad based and there are several drivers of this growth:
1. 2QFY21 was the 3rd consecutive quarter of $ 200mn+ net TCV deal wins. 2QFY21had highest ever TCV deal wins of $ 360mn. The momentum of deal wins is translating in good growth for the direct core channel.
2. Mphasis has seen good growth in existing strategic accounts as well as from new clients. Growth from new clients was 30% YoY in 2QFY21.
3. Mphasis has also been enjoying strong growth for the past 6 quarters from their European business. European business revenue growth was ~27%-28% YoY for 2QFY21.
● Mphasis has already crossed the pre-pandemic peak revenue in 2QFY21 itself. Mr Rakesh expects that the current growth trajectory should continue and Mphasis can deliver mid to high single digit revenue growth for FY21E.
● Mphasis’s MRC (Minimum Revenue Commitment) from strategic account of DXC expires in Sep-21. They still have $ 200 mn to be consumed in next 4 quarters. Post that, DXC channel will become like any other client for Mphasis and management is not worried about retaining the clients.
● Mphasis has stuck to their EBIT margin guidance band of 15.5%-16.5%. Management’s philosophy going into FY21 has been to maximize the growth potential in the market considering a lot of Mphasis’ digital capabilities are in high demand. Mphasis has prioritized growth over margin expansion, at the same time held margins steady.
● Mphasis istaking the margin operating efficiencies and re-investing it back into competency building, sales expansion, and investingin ramp up of recent deal wins.

Consensus Estimate (Source: market screener website)
● The closing price of MPHASIS was ₹ 1,356/- as of 26-October-2020. It traded at 20.7x/ 17.9x/ 15.8x the consensus EPS estimate of ₹ 65.6/75.8/85.7 for FY21E/ FY22E/ FY23E respectively.
● The consensus target price of ₹ 1,483/- implies a PE multiple of 17.3x on FY23E EPS of ₹85.7/-.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”